| pubmed-article:18990175 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:18990175 | lifeskim:mentions | umls-concept:C1457887 | lld:lifeskim |
| pubmed-article:18990175 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:18990175 | lifeskim:mentions | umls-concept:C0008976 | lld:lifeskim |
| pubmed-article:18990175 | lifeskim:mentions | umls-concept:C0034656 | lld:lifeskim |
| pubmed-article:18990175 | lifeskim:mentions | umls-concept:C0878773 | lld:lifeskim |
| pubmed-article:18990175 | lifeskim:mentions | umls-concept:C1274040 | lld:lifeskim |
| pubmed-article:18990175 | lifeskim:mentions | umls-concept:C1099677 | lld:lifeskim |
| pubmed-article:18990175 | lifeskim:mentions | umls-concept:C0439609 | lld:lifeskim |
| pubmed-article:18990175 | pubmed:issue | 9 | lld:pubmed |
| pubmed-article:18990175 | pubmed:dateCreated | 2008-12-5 | lld:pubmed |
| pubmed-article:18990175 | pubmed:abstractText | To examine the effects of the antimuscarinic agent solifenacin on urinary urgency, using a range of novel and established outcome measures, as urgency is the principal symptom of the overactive bladder syndrome (OAB). | lld:pubmed |
| pubmed-article:18990175 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18990175 | pubmed:language | eng | lld:pubmed |
| pubmed-article:18990175 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18990175 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:18990175 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18990175 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18990175 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18990175 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18990175 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:18990175 | pubmed:month | Nov | lld:pubmed |
| pubmed-article:18990175 | pubmed:issn | 1464-410X | lld:pubmed |
| pubmed-article:18990175 | pubmed:author | pubmed-author:SlackMarkM | lld:pubmed |
| pubmed-article:18990175 | pubmed:author | pubmed-author:CardozoLindaL | lld:pubmed |
| pubmed-article:18990175 | pubmed:author | pubmed-author:WrightMarkM | lld:pubmed |
| pubmed-article:18990175 | pubmed:author | pubmed-author:MilaniRodolfo... | lld:pubmed |
| pubmed-article:18990175 | pubmed:author | pubmed-author:ArañóPedroP | lld:pubmed |
| pubmed-article:18990175 | pubmed:author | pubmed-author:BolodeokuJohn... | lld:pubmed |
| pubmed-article:18990175 | pubmed:author | pubmed-author:HessdörferElk... | lld:pubmed |
| pubmed-article:18990175 | pubmed:author | pubmed-author:DewildeLucL | lld:pubmed |
| pubmed-article:18990175 | pubmed:author | pubmed-author:DrogendijkTed... | lld:pubmed |
| pubmed-article:18990175 | pubmed:author | pubmed-author:SUNRISE... | lld:pubmed |
| pubmed-article:18990175 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:18990175 | pubmed:volume | 102 | lld:pubmed |
| pubmed-article:18990175 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:18990175 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:18990175 | pubmed:pagination | 1120-7 | lld:pubmed |
| pubmed-article:18990175 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
| pubmed-article:18990175 | pubmed:meshHeading | pubmed-meshheading:18990175... | lld:pubmed |
| pubmed-article:18990175 | pubmed:meshHeading | pubmed-meshheading:18990175... | lld:pubmed |
| pubmed-article:18990175 | pubmed:meshHeading | pubmed-meshheading:18990175... | lld:pubmed |
| pubmed-article:18990175 | pubmed:meshHeading | pubmed-meshheading:18990175... | lld:pubmed |
| pubmed-article:18990175 | pubmed:meshHeading | pubmed-meshheading:18990175... | lld:pubmed |
| pubmed-article:18990175 | pubmed:meshHeading | pubmed-meshheading:18990175... | lld:pubmed |
| pubmed-article:18990175 | pubmed:meshHeading | pubmed-meshheading:18990175... | lld:pubmed |
| pubmed-article:18990175 | pubmed:meshHeading | pubmed-meshheading:18990175... | lld:pubmed |
| pubmed-article:18990175 | pubmed:meshHeading | pubmed-meshheading:18990175... | lld:pubmed |
| pubmed-article:18990175 | pubmed:meshHeading | pubmed-meshheading:18990175... | lld:pubmed |
| pubmed-article:18990175 | pubmed:meshHeading | pubmed-meshheading:18990175... | lld:pubmed |
| pubmed-article:18990175 | pubmed:meshHeading | pubmed-meshheading:18990175... | lld:pubmed |
| pubmed-article:18990175 | pubmed:meshHeading | pubmed-meshheading:18990175... | lld:pubmed |
| pubmed-article:18990175 | pubmed:meshHeading | pubmed-meshheading:18990175... | lld:pubmed |
| pubmed-article:18990175 | pubmed:year | 2008 | lld:pubmed |
| pubmed-article:18990175 | pubmed:articleTitle | Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double-blind, placebo-controlled, rising-dose trial. | lld:pubmed |
| pubmed-article:18990175 | pubmed:affiliation | King's College Hospital, Department of Urogynaecology, London, UK. lcardozo@compuserve.com | lld:pubmed |
| pubmed-article:18990175 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:18990175 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:18990175 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:18990175 | pubmed:publicationType | Multicenter Study | lld:pubmed |
| pubmed-article:18990175 | pubmed:publicationType | Clinical Trial, Phase III | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18990175 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18990175 | lld:pubmed |
